Indeed, available evidence suggests that synthetic PPARγ agonists such as rosiglitazone and troglitazone, but also the natural PPARγ ligand 15-deoxy-Delta (12,14)-prostaglandin J2, can improve arthritis in murine models (122, 123). Here, PPARG is linked to arthritic joint disease.